Pharmacogenomics of pediatric asthma

Indian Journal of Human Genetics

Volumn 16, Issue 3, 2010, Pages 111-118

  Gupta, Sarika ^a   Awasthi, Shally ^a  

^a CSMMU   (India)

Author keywords

Asthma; pharamacogenomics; polymorphism; variability in response

Indexed keywords

ATRELEUTON; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CICLESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DOXOFYLLINE; FLUNISOLIDE; FLUTICASONE PROPIONATE; FORMOTEROL; HYDROCORTISONE; IMMUNOGLOBULIN E ANTIBODY; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; METHYLPREDNISOLONE; METHYLXANTHINE; MONTELUKAST; NEDOCROMIL; NONSTEROID ANTIINFLAMMATORY AGENT; OMALIZUMAB; PREDNISOLONE; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; UNINDEXED DRUG; ZAFIRLUKAST; ZILEUTON;

AMINO ACID SUBSTITUTION; ASTHMA; CHILD; DNA POLYMORPHISM; DRUG MECHANISM; ENVIRONMENTAL FACTOR; FORCED EXPIRATORY VOLUME; GENE DELETION; GENE INTERACTION; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; PHARMACOGENOMICS; RECEPTOR GENE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TANDEM REPEAT; TREATMENT RESPONSE;

EID: 78650108089     PISSN: 09716866     EISSN: 1998362X     Source Type: Journal    
DOI: 10.4103/0971-6866.73398     Document Type: Review

References (46)

1. National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051). Full text Available from: www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm [Last accessed on 2007 Sep 1].
2. Peters SP. Heterogeneity in the pathology and treatment of asthma. Am J Med 2003;115:49S-54.
3. Mannino DM, Homa DM, Akinbami LJ, Moorman JE, Gwynn C, Redd SC. Surveillance for asthma-United States, 1980-1999. MMWR Surveill Summ 2002;51:1-13.
4. Moorman JE, Rudd RA, Johnson CA, King M, Minor P, Bailey C, et al. National surveillance for asthma-United States, 1980-2004. MMWR Surveill Summ 2007;56:1-54.
5. Awasthi S, Kalra E, Roy S, Awasthi S. Prevalence and Risk Factors of Asthma and Wheeze in School going Children in Lucknow, North India. Indian Pediatrics 2004;41:1205-10.
6. Taylor WR, Newacheck PW. Impact of childhood asthma on health. Pediatrics 1992;90:657-62.
7. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836-44.
8. Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002;109:410-8.
9. Ledford D, Apter A, Brenner AM, Rubin K, Prestwood K, Frieri M, et al. Osteoporosis in the corticosteroid-treated patient with asthma. J Allergy Clin Immunol 1998;102:353-62.
10. Lazarus SC, Lee T, Kemp JP, Wenzel S, Dube LM, Ochs RF, et al. Safety and clinical efficacy of zileuton in patients with chronic asthma. Am J Manag Care 1998;4:841-8.
11. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull 2000;56:1054-70.
12. Palmer LJ, Cookson WO. Using single nucleotide polymorphisms as a means to understanding the pathophysiology of asthma. Respir Res 2001;2:102-12.
13. Michael E. Wechsler and Elliot Israel. How Pharmacogenomics will play a role in the management of asthma. Am J Respir Crit Care Med 2005;172:12-8.
14. Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993;8:334-9.
15. Dewar JC, Wheatley AP, Venn A, Morrison JF, Britton J, Hall IP. Beta2-adrenoceptor polymorphisms are in linkage disequilibrium but are not associated with asthma in an adultpopulation. Clin Exp Allergy 1998;28:442-8.
16. Turki J, Pak J, Green SA, Martin RJ, Liggett SB. Genetic polymorphisms of the beta2-adrenergic receptor in nocturnal and non-nocturnal asthma. Clin Invest 1995;95:1635-41.
17. Martinez FD, Graves PE, Baldini M, Solomon S, Enckson R. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with andwithout a history of wheezing. Clin Invest 1997;100:3184-8.
18. Hall IP, Wheatley A, Wilding P, Liggett SB. Association of the Glu-27 beta2-adrenoceptor polymorphism with lower airway reactivity in asthmatic subjects. Lancet 1995;345:1213-4.
19. Lima JJ, Thomason DB, Mohamed MH, Eberle LV, Self TH, Johnson JA. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 1999;65:519-25.
20. Corvol H, Burchard EG. Pharmacogenetic response to albuterol among asthmatics. Pharmacogenomics 2008;9:505-10.
21. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, Use of regularly scheduled albuterol treatment in asthma: Genotype-stratified, randomised, placebo-controlled crossover trial. Lancet 2004;364:1505-12.
22. Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI. Asthma exacerbations during long term beta agonist use: Influence of beta (2) adrenoceptor polymorphism. Thorax 2000;55:762-7.
23. Bleecker ER, Yancey SW, Baitinger L, Edwards L, Klotsman M, Anderson W, et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol 2006;118:809-16.
24. Litonjua AA, Lasky-Su J, Schneiter K, Tantisira KG, Lazarus R, Klanderman B, et al. ARG1 is a novel bronchodilator response gene: Screening and replication in four asthma cohorts. Am J Respir Crit Care Med 2008;178:688-94.
25. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull 2000;56:1054-70.
26. Adcock IM, Lane SJ, Brown CR, Lee TH, Barnes PJ. Abnormal glucocorticoid receptor-activator protein 1 interaction in steroid-resistant asthma. J Exp Med 1995;182:1951-8.
27. Mathieu M, Gougat C, Jaffuel D, Danielsen M, Godard P, Bousquet J, et al. The glucocorticoid receptor gene as a candidate for gene therapy in asthma. Gene Ther 1999;6:245-52.
28. Scheinman RI, Gualberto A, Jewell CM, Cidlowski JA, Baldwin AS. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol 1995;15:943-53.
29. Lane SJ, Adcock IM, Richards D, Hawrylowicz C, Barnes PJ, Lee TH. Corticosteroid-resistant bronchial asthma is associated with increased c-Fos expression in monocytes and T lymphocytes. Clin Invest 1998;102:2156-64.
30. Bray PJ, Cotton RG. Variations of the human glucocorticoid receptor gene (NR3C1): Pathological and in vitro mutations and polymorphisms. Hum mutat 2003;21:557-68.
31. Leung DY, Spahn JD, Szefler SJ. Steroid-unresponsive asthma. semin respire Crit Care med 2002;23:387-98.
32. Tantisira KG, Lake S, Silverman ES, Palmer LJ, Lazarus R, Silverman EK, et al. Corticosteroid pharmacogenetics: Association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum mol Genet 2004;13:1353-9.
33. Tantisira KG, Hwang ES, Raby BA, Silverman ES, Lake SL, Richter BG, et al. TBX21: A functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci USA 2004;101:18099-104
34. Drazen JM, Yandava C, Dube L, Szczerback N, Hippensteel R, Pillari A, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999;22:170-2.
35. Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of asprin induced asthma. Lancet 1997;350:1599-600.
36. Anderson W, Kalberg C, Edwards L, Fling M, Binnie C, Nguyen Q, et al. Effects of polymorphisms in the promoter region of 5-lipoxygenase and ltc4 synthase on the clinical response to zafirlukast and fluticasone. Eur Respir J 2000;16:183s.
37. Sampson AP, Siddiqui S, Buchanan D, Howarth PH, Holgate ST, Holloway JW, et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000;55:S28-31
38. Fenech AG, Ebejer MJ, Felice AE, Ellulmicallef R, Hall IP. Mutation screening of the muscarinic M2 and M3 receptor genes in normal and asthmatic subjects. Br J Pharmacol 2001;133:43-8.
39. Yamamoto T, Yamashita N, Kuwabara M, Nakano J, Sugimoto H, Akiyama K, et al. Mutation screening of the muscarinic M2 and M3 receptor genes in asthmatics, outgrow subjects, and normal controls. Ann Genet 2002;45:109-13.
40. Fenech AG, Billington CK, Swan C, Richards S, Hunter T, Ebejer MJ, et al. Novel polymorphisms influencing transcription of the human CHRM2 gene in airway smooth muscle. Am J Respir Cell Mol Biol 2004;30:678-86.
41. Schudt C, Tenor H, Hatzelmann A. PDE isoenzyme as targets for anti-asthma drugs. Eur Respir J 1995;8:1179-83.
42. Polson JB, Krzanowski JJ, Goldman AL, Szentivanyi A. Inhibition of human pulmonary phosphodiesterase activity by therapeutic levels of theophylline. Clin Exp Pharmacol Physiol 1978;5:535-9.
43. Chiba M, Xu X, Nishime JA, Balani SK, Lin JH. Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in human. Drug Metab Dispos 1997;25:1022-31.
44. Manchee GR, Eddershaw PJ, Ranshaw LE, Herriott D, Park GR, Bayliss MK, et al. The aliphatic oxidation of salmeterol to alpha-hydroxysalmeterol in human liver microsomes is catalyzed by CYP3A. Drug Metab Dispos 1996;24:555-9
45. Obase Y, Shimoda T, Kawano T, Saeki S, Tomari SY, Mitsuta-Izaki K, et al. Polymorphism in the CYP1A2 gene and theophylline metabolism in patients with asthma. Clin Pharmacol Ther 2003;173:519-26.
46. Raby BA, Van SK, Lazarus R, Celedon JC, Silverman EK, Weiss ST. Eotaxin polymorphisms and serum total IgE levels in children with asthma. Allergy Clin Immunol 2006;117:298-305.